These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 10319741)

  • 21. Detection of visual activation in the rat brain using 2-deoxy-2-[(18)F]fluoro-D: -glucose and statistical parametric mapping (SPM).
    Soto-Montenegro ML; Vaquero JJ; Pascau J; Gispert JD; García-Barreno P; Desco M
    Mol Imaging Biol; 2009; 11(2):94-9. PubMed ID: 19037612
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of lorazepam on brain activity pattern during an anxiety symptom provocation challenge.
    Schunck T; Mathis A; Erb G; Namer IJ; Demazières A; Luthringer R
    J Psychopharmacol; 2010 May; 24(5):701-8. PubMed ID: 19460871
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Regional cerebral function determined by FDG-PET in healthy volunteers: normal patterns and changes with age.
    Loessner A; Alavi A; Lewandrowski KU; Mozley D; Souder E; Gur RE
    J Nucl Med; 1995 Jul; 36(7):1141-9. PubMed ID: 7790936
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Voxel based comparison of glucose metabolism in the differential diagnosis of the multiple system atrophy using statistical parametric mapping.
    Juh R; Pae CU; Lee CU; Yang D; Chung Y; Suh T; Choe B
    Neurosci Res; 2005 Jul; 52(3):211-9. PubMed ID: 15927722
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Depression of thalamic metabolism by lorazepam is associated with sleepiness.
    Volkow ND; Wang GJ; Hitzemann R; Fowler JS; Pappas N; Lowrimore P; Burr G; Pascani K; Overall J; Wolf AP
    Neuropsychopharmacology; 1995 Apr; 12(2):123-32. PubMed ID: 7779240
    [TBL] [Abstract][Full Text] [Related]  

  • 26. 11C-diprenorphine binding in Huntington's disease: a comparison of region of interest analysis with statistical parametric mapping.
    Weeks RA; Cunningham VJ; Piccini P; Waters S; Harding AE; Brooks DJ
    J Cereb Blood Flow Metab; 1997 Sep; 17(9):943-9. PubMed ID: 9307607
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of percent thresholding on the extraction of [18F]fluorodeoxyglucose positron emission tomographic region-of-interest data.
    Rottenberg DA; Moeller JR; Strother SC; Dhawan V; Sergi ML
    J Cereb Blood Flow Metab; 1991 Mar; 11(2):A83-8. PubMed ID: 1997493
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Diminished glucose transport and phosphorylation in Alzheimer's disease determined by dynamic FDG-PET.
    Piert M; Koeppe RA; Giordani B; Berent S; Kuhl DE
    J Nucl Med; 1996 Feb; 37(2):201-8. PubMed ID: 8667045
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Regional brain metabolic response to lorazepam in subjects at risk for alcoholism.
    Volkow ND; Wang GJ; Begleiter H; Hitzemann R; Pappas N; Burr G; Pascani K; Wong C; Fowler JS; Wolf AP
    Alcohol Clin Exp Res; 1995 Apr; 19(2):510-6. PubMed ID: 7625590
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Anterior limbic alpha-like activity: a low resolution electromagnetic tomography study with lorazepam challenge.
    Connemann BJ; Mann K; Lange-Asschenfeldt C; Ruchsow M; Schreckenberger M; Bartenstein P; Gründer G
    Clin Neurophysiol; 2005 Apr; 116(4):886-94. PubMed ID: 15792898
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of voxel- and volume-of-interest-based analyses in FDG PET scans of HIV positive and healthy individuals.
    Liow JS; Rehm K; Strother SC; Anderson JR; Morch N; Hansen LK; Schaper KA; Rottenberg DA
    J Nucl Med; 2000 Apr; 41(4):612-21. PubMed ID: 10768561
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cerebral metabolic differences in Parkinson's and Alzheimer's diseases matched for dementia severity.
    Vander Borght T; Minoshima S; Giordani B; Foster NL; Frey KA; Berent S; Albin RL; Koeppe RA; Kuhl DE
    J Nucl Med; 1997 May; 38(5):797-802. PubMed ID: 9170449
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Reproducibility of metabolic measurements in malignant tumors using FDG PET.
    Weber WA; Ziegler SI; Thödtmann R; Hanauske AR; Schwaiger M
    J Nucl Med; 1999 Nov; 40(11):1771-7. PubMed ID: 10565769
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Statistical mapping analysis of serotonin synthesis images generated in healthy volunteers using positron-emission tomography and alpha-[11C]methyl-L-tryptophan.
    Okazawa H; Leyton M; Benkelfat C; Mzengeza S; Diksic M
    J Psychiatry Neurosci; 2000 Sep; 25(4):359-70. PubMed ID: 11022401
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Quantification of serial tumor glucose metabolism.
    Wu HM; Hoh CK; Huang SC; Yao WJ; Phelps ME; Hawkins RA
    J Nucl Med; 1996 Mar; 37(3):506-13. PubMed ID: 8772657
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Anatomic standardization: linear scaling and nonlinear warping of functional brain images.
    Minoshima S; Koeppe RA; Frey KA; Kuhl DE
    J Nucl Med; 1994 Sep; 35(9):1528-37. PubMed ID: 8071705
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Glucose metabolism in human malignant gliomas measured quantitatively with PET, 1-[C-11]glucose and FDG: analysis of the FDG lumped constant.
    Spence AM; Muzi M; Graham MM; O'Sullivan F; Krohn KA; Link JM; Lewellen TK; Lewellen B; Freeman SD; Berger MS; Ojemann GA
    J Nucl Med; 1998 Mar; 39(3):440-8. PubMed ID: 9529289
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dexamethasone treatment and plasma glucose levels: relevance for fluorine-18-fluorodeoxyglucose uptake measurements in gliomas.
    Roelcke U; Blasberg RG; von Ammon K; Hofer S; Vontobel P; Maguire RP; Radü EW; Herrmann R; Leenders KL
    J Nucl Med; 1998 May; 39(5):879-84. PubMed ID: 9591593
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Estrogen use and brain metabolic change in postmenopausal women.
    Rasgon NL; Silverman D; Siddarth P; Miller K; Ercoli LM; Elman S; Lavretsky H; Huang SC; Phelps ME; Small GW
    Neurobiol Aging; 2005 Feb; 26(2):229-35. PubMed ID: 15582750
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Determination of regional rate constants from dynamic FDG-PET studies in Parkinson's disease.
    Piert M; Koeppe RA; Giordani B; Minoshima S; Kuhl DE
    J Nucl Med; 1996 Jul; 37(7):1115-22. PubMed ID: 8965180
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.